Search

Displaying results 4141 - 4150 of 8575 in total
  1. Drug

    Artemotil

    go.drugbank.com/drugs/DB13851
    Approved

    Artemotil, also known as β-arteether, is a semi-synthetic derivative of artemisinin and a fast acting blood schizonticide specifically indicated for the treatment of chloroquine-resistant _Plasmodium falciparum

  2. Drug

    BMS-770767

    go.drugbank.com/drugs/DB18902
    Investigational

    BMS-770767 is under investigation in clinical trial NCT01058083 (Safety Study of BMS-770767 in Subjects With Hypercholesterolemia).

  3. Drug

    Donidalorsen

    go.drugbank.com/drugs/DB18751
    ApprovedInvestigational

    [L53788] Donidalorsen was approved by the FDA in August 2025 for prophylactic use to prevent HAE attacks.[L53783,L53788] It is the first RNA-targeted therapy approved for HAE.[L53783]

  4. Drug

    Diflunisal

    go.drugbank.com/drugs/DB00861
    Approved

    Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the arachidonic acid pathway.

    Products: Dolobid Tab 500mg, Nu-diflunisal Tab 500mg
  5. Drug

    Ammonia N-13

    go.drugbank.com/drugs/DB09326
    Approved

    The active ingredient, [13N] ammonia, has the molecular formula of 13NH3 with a molecular weight of 16.02.

  6. Drug

    Paltusotine

    go.drugbank.com/drugs/DB16277
    ApprovedInvestigational

    [A274476] Paltusotine was approved by the FDA on September 25, 2025 for the treatment of acromegaly in adults.[L54061]

  7. Drug

    Frovatriptan

    go.drugbank.com/drugs/DB00998
    Approved

    Frovatriptan is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head.

  8. Drug

    Azvudine

    go.drugbank.com/drugs/DB16407
    Investigational

    Azvudine is under investigation in clinical trial NCT04668235 (Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (Sars-cov-2 Infected)).

  9. Drug

    GI-5005

    go.drugbank.com/drugs/DB05942
    Investigational

    Tarmogens are believed to activate both an innate immune response via Toll-like receptors (TLRs), as well as an adaptive, antigen specific cellular immune response.

  10. Drug

    Briakinumab

    go.drugbank.com/drugs/DB05459
    Investigational

    As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. … It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha.